Related references
Note: Only part of the references are listed.Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy
Surbhi Gupta et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2022)
Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial
Marcus Maurer et al.
CLINICAL AND TRANSLATIONAL ALLERGY (2022)
Description and Characterization of a Novel Human Mast Cell Line for Scientific Study
Arnold S. Kirshenbaum et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity
Clive Metcalfe et al.
MABS (2019)
Molecular and functional analysis of monoclonal antibodies in support of biologics development
Xin Wang et al.
PROTEIN & CELL (2018)
On the glycosylation aspects of biosimilarity
Laszlo Hajba et al.
DRUG DISCOVERY TODAY (2018)
Maintaining consistent quality and clinical performance of biopharmaceuticals
William C. Lamanna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Analytical comparability study of recombinant monoclonal antibody therapeutics
Alexandre Ambrogelly et al.
MABS (2018)
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
Corrado Pelaia et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
Laurent Magnenat et al.
MABS (2017)
Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic
Fernando de Mora et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2017)
Biosimilarity Versus Manufacturing Change: Two Distinct Concepts
Paul Declerck et al.
PHARMACEUTICAL RESEARCH (2016)
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
Balazs Vezer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®)
Hans-Peter Hofmann et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Protein post-translational modifications and regulation of pluripotency in human stem cells
Yu-Chieh Wang et al.
CELL RESEARCH (2014)
Physicochemical characterization of Remsima®
Soon Kwan Jung et al.
MABS (2014)
Use of Humanised Rat Basophilic Leukaemia Cell Line RS-ATL8 for the Assessment of Allergenicity of Schistosoma mansoni Proteins
Daniel Wan et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Analytical strategies for the characterization of therapeutic monoclonal antibodies
Szabolcs Fekete et al.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY (2013)
Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells
Amelie Croset et al.
JOURNAL OF BIOTECHNOLOGY (2012)
Share Paper
